MAAT PHARMA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.22 EUR | +4.05% |
|
-11.99% | +17.77% |
| May. 08 | Mickey Mouse on Wall Street |  |
| Apr. 15 | MaaT Pharma: positive data in graft-versus-host disease | CF |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 131.9 | 79.15 | 80.99 | 114.2 | - | - |
| Enterprise Value (EV) 1 | 94.45 | 55.21 | 80.99 | 105.6 | 106.3 | 1,850 |
| P/E ratio | - | - | -4.11 x | -3.52 x | -3.45 x | -3.65 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 136 x | - | 36.4 x | 28.6 x | 26 x | 11.7 x |
| EV / Revenue | 97.2 x | - | 36.4 x | 26.4 x | 24.2 x | 189 x |
| EV / EBITDA | -11 x | - | -4.25 x | -3.64 x | -3.63 x | -74.6 x |
| EV / FCF | -11.6 x | -4.16 x | - | -2.98 x | -6.52 x | 280 x |
| FCF Yield | -8.65% | -24% | - | -33.5% | -15.3% | 0.36% |
| Price to Book | - | - | - | 19.6 x | -5.24 x | - |
| Nbr of stocks (in thousands) | 9,884 | 9,894 | 11,603 | 13,897 | - | - |
| Reference price 2 | 13.35 | 8.000 | 6.980 | 8.220 | 8.220 | 8.220 |
| Announcement Date | 4/14/22 | 3/31/23 | 3/28/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 2.136 | 0.972 | - | 2.228 | 4 | 4.4 | 9.8 |
| EBITDA 1 | - | -8.565 | - | -19.07 | -29 | -29.3 | -24.8 |
| EBIT 1 | - | - | - | -19.94 | -29.5 | -29.8 | -25.9 |
| Operating Margin | - | - | - | -895.11% | -737.5% | -677.27% | -264.29% |
| Earnings before Tax (EBT) 1 | - | - | - | -19.72 | -29 | -32.9 | -26.2 |
| Net income 1 | - | - | - | -19.72 | -29.6 | -29.9 | -26.2 |
| Net margin | - | - | - | -884.96% | -740% | -679.55% | -267.35% |
| EPS 2 | -25.70 | - | - | -1.700 | -2.335 | -2.385 | -2.250 |
| Free Cash Flow 1 | - | -8.167 | -13.27 | - | -35.43 | -16.3 | 6.6 |
| FCF margin | - | -840.23% | - | - | -885.83% | -370.45% | 67.35% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 10/4/21 | 4/14/22 | 3/31/23 | 3/28/24 | - | - | - |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | 1,736 |
| Net Cash position 1 | - | 37.5 | 23.9 | - | 8.6 | 7.9 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | -69.98 x |
| Free Cash Flow 1 | - | -8.17 | -13.3 | - | -35.4 | -16.3 | 6.6 |
| ROE (net income / shareholders' equity) | - | - | - | - | -199% | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | - | - | - | 0.4200 | -1.570 | - |
| Cash Flow per Share 2 | - | - | -1.270 | - | -2.060 | 0.3600 | 3.200 |
| Capex 1 | - | 0.24 | 0.66 | - | 1.93 | 1.77 | 1.45 |
| Capex / Sales | - | 24.49% | - | - | 48.33% | 40.15% | 14.8% |
| Announcement Date | 10/4/21 | 4/14/22 | 3/31/23 | 3/28/24 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
8.22
EUR
Average target price
14.6
EUR
Spread / Average Target
+77.62%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +17.77% | 124M | |
| +9.42% | 115B | |
| +11.84% | 106B | |
| -1.05% | 21.96B | |
| -14.15% | 21.87B | |
| -5.29% | 19.21B | |
| -4.16% | 18.08B | |
| -38.29% | 17.71B | |
| +7.99% | 14.32B | |
| +36.24% | 12.42B |
- Stock Market
- Equities
- MAAT Stock
- Financials MaaT Pharma
